Marker Therapeutics (MRKR) Competitors $1.04 +0.01 (+0.97%) Closing price 04:00 PM EasternExtended Trading$1.03 -0.01 (-0.48%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MRKR vs. BCAB, ZIVO, ATNM, AADI, INMB, IPSC, ADAP, VNRX, ESLA, and KPTIShould you be buying Marker Therapeutics stock or one of its competitors? The main competitors of Marker Therapeutics include BioAtla (BCAB), ZIVO Bioscience (ZIVO), Actinium Pharmaceuticals (ATNM), Aadi Bioscience (AADI), INmune Bio (INMB), Century Therapeutics (IPSC), Adaptimmune Therapeutics (ADAP), VolitionRx (VNRX), Estrella Immunopharma (ESLA), and Karyopharm Therapeutics (KPTI). These companies are all part of the "pharmaceutical products" industry. Marker Therapeutics vs. Its Competitors BioAtla ZIVO Bioscience Actinium Pharmaceuticals Aadi Bioscience INmune Bio Century Therapeutics Adaptimmune Therapeutics VolitionRx Estrella Immunopharma Karyopharm Therapeutics BioAtla (NASDAQ:BCAB) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation and risk. Do analysts prefer BCAB or MRKR? Marker Therapeutics has a consensus target price of $10.25, indicating a potential upside of 885.58%. Given Marker Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Marker Therapeutics is more favorable than BioAtla.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioAtla 1 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75Marker Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.00 Does the media refer more to BCAB or MRKR? In the previous week, BioAtla had 3 more articles in the media than Marker Therapeutics. MarketBeat recorded 3 mentions for BioAtla and 0 mentions for Marker Therapeutics. BioAtla's average media sentiment score of 0.00 equaled Marker Therapeutics'average media sentiment score. Company Overall Sentiment BioAtla Neutral Marker Therapeutics Neutral Which has stronger valuation & earnings, BCAB or MRKR? Marker Therapeutics has lower revenue, but higher earnings than BioAtla. Marker Therapeutics is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioAtla$11M3.68-$69.78M-$1.10-0.63Marker Therapeutics$6.59M2.04-$10.73M-$1.37-0.76 Is BCAB or MRKR more profitable? BioAtla has a net margin of 0.00% compared to Marker Therapeutics' net margin of -271.12%. Marker Therapeutics' return on equity of -114.59% beat BioAtla's return on equity.Company Net Margins Return on Equity Return on Assets BioAtlaN/A -1,177.18% -137.51% Marker Therapeutics -271.12%-114.59%-90.31% Which has more volatility & risk, BCAB or MRKR? BioAtla has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500. Comparatively, Marker Therapeutics has a beta of 1.47, indicating that its share price is 47% more volatile than the S&P 500. Do insiders & institutionals have more ownership in BCAB or MRKR? 77.2% of BioAtla shares are held by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are held by institutional investors. 11.2% of BioAtla shares are held by insiders. Comparatively, 7.8% of Marker Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryBioAtla and Marker Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get Marker Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MRKR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MRKR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRKR vs. The Competition Export to ExcelMetricMarker TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.46M$2.62B$6.11B$10.62BDividend YieldN/A57.79%5.72%4.85%P/E Ratio-0.7623.5929.2227.30Price / Sales2.04587.20491.48184.03Price / CashN/A27.2425.8230.35Price / Book0.605.4112.476.65Net Income-$10.73M$33.06M$3.32B$276.14M7 Day Performance-1.89%1.33%1.87%0.01%1 Month Performance9.47%10.15%8.40%3.60%1 Year Performance-71.89%-2.20%63.49%32.76% Marker Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRKRMarker Therapeutics3.7239 of 5 stars$1.04+1.0%$10.25+885.6%-70.7%$13.46M$6.59M-0.7660BCABBioAtla0.4972 of 5 stars$0.91+4.9%N/A-68.4%$50.94M$11M-0.8360News CoverageGap UpZIVOZIVO Bioscience0.5951 of 5 stars$13.20+1.5%N/A-32.5%$50.85M$15.85K-2.7010Gap UpATNMActinium Pharmaceuticals2.1038 of 5 stars$1.61+8.1%$4.50+179.5%-16.5%$50.23MN/A-1.1630AADIAadi BioscienceN/A$2.02-6.9%N/A+4.7%$49.89M$25.07M-0.8940INMBINmune Bio1.7809 of 5 stars$1.83-1.6%$18.50+910.9%-62.4%$49.45M$10K-0.7410IPSCCentury Therapeutics2.5816 of 5 stars$0.55-3.3%$3.75+581.9%-64.3%$49.13M$6.59M-1.90170News CoverageAnalyst DowngradeADAPAdaptimmune Therapeutics1.9378 of 5 stars$0.18-2.6%$1.35+650.5%-93.0%$49.01M$178.03M-0.28490News CoverageGap DownVNRXVolitionRx2.8948 of 5 stars$0.45-2.5%$3.50+673.1%-38.9%$48.71M$1.32M-1.2680Positive NewsGap UpHigh Trading VolumeESLAEstrella Immunopharma2.8926 of 5 stars$1.50+16.3%$16.00+966.7%+128.7%$47.81MN/A-5.77N/APositive NewsShort Interest ↓High Trading VolumeKPTIKaryopharm Therapeutics4.2823 of 5 stars$5.62+2.2%$18.20+223.8%-50.4%$47.69M$145.24M-0.39380 Related Companies and Tools Related Companies BioAtla Alternatives ZIVO Bioscience Alternatives Actinium Pharmaceuticals Alternatives Aadi Bioscience Alternatives INmune Bio Alternatives Century Therapeutics Alternatives Adaptimmune Therapeutics Alternatives VolitionRx Alternatives Estrella Immunopharma Alternatives Karyopharm Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MRKR) was last updated on 10/21/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Marker Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Marker Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MRKR Stock Alerts